Publications

Highlighting AllCaN Oesophageal's Expertise

The following publications have all contributed to the AllCaN Oesophageal programme and highlight the expertise of the AllCaN project team and its collaborators (links included).

2024

• A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium.

• Survival outcomes in early-onset oesophageal adenocarcinoma patients: A systematic review and meta-analyses.

• Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: the EMERALD multicentre study.

• Liquid biopsy to diagnose esophageal adenocarcinoma

• Perspective: Peer Evaluation of Recommendations for CONSORT Guidelines for Randomized Controlled Trials in Nutrition.

• Obesity, Dietary Fats, and Gastrointestinal Cancer Risk-Potential Mechanisms Relating to Lipid Metabolism and Inflammation.

• Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma.

• An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.

• Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

2023

• Potential of damage associated molecular patterns in synergising radiation and the immune response in oesophageal cancer.

• PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.

• Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.

• Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.

• Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.

2022

• Early-Onset Cancers in Adults: A Review of Epidemiology, Supportive Care Needs and Future Research Priorities.

• FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy.

• Prognostic, Diagnostic and Predictive Biomarkers in the Barrett's Oesophagus-Adenocarcinoma Disease Sequence.

• Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.

• Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.

• Telehealth Delivery of a Multi-Disciplinary Rehabilitation Programme for Upper Gastro-Intestinal Cancer: ReStOre Home Feasibility Study.

• The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.

• The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy.

• Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.

• PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours.

• PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.

• The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition.

2021

• Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer.

• Opposing Immune-Metabolic Signature in Visceral Versus Subcutaneous Adipose Tissue in Patients with Adenocarcinoma of the Oesophagus and the Oesophagogastric Junction.

• Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.

• A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance.

• The Effectiveness of Nutrition Interventions Combined with Exercise in Upper Gastrointestinal Cancers: A Systematic Review.

• ReStOre@Home: Feasibility study of a virtually delivered 12-week multidisciplinary rehabilitation programme for survivors of upper gastrointestinal (UGI) cancer - study protocol.

• Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma.

• Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.

• The Impact of the COVID-19 Pandemic on Barrett's Esophagus and Esophagogastric Cancer.

• A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance.

2020

• Perspectives of Esophageal Cancer Survivors on Diagnosis, Treatment, and Recovery.

• Patient and family co-developed participant information to improve recruitment rates, retention, and patient understanding in the Rehabilitation Strategies Following Oesophago-gastric and Hepatopancreaticobiliary Cancer (ReStOre II) trial: Protocol for a study within a trial (SWAT).

• Epidemiology of esophageal cancer: update in global trends, etiology and risk factors.

• A study of the immune infiltrate and patient outcomes in esophageal cancer.

• Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma.

• Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.

• Characterizing caspase-1 involvement during esophageal disease progression.

• Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre II): a protocol for a randomized controlled trial.

• Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.

• Esophageal, gastric cancer and immunotherapy: small steps in the right direction?

• Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett's dysplasia using digital pathology.

2019

• Physical recovery in the first six months following oesophago-gastric cancer surgery. Identifying rehabilitative needs: a qualitative interview study.

• Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrett's Esophagus Compared to Esophageal Adenocarcinoma.

• Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma.

• TNF-α/IL-1β-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung.

• Altered T Cell Migratory Capacity in the Progression from Barrett Oesophagus to Oesophageal Adenocarcinoma.

2018

• The Mitochondrial Genes BAK1, FIS1 and SFN are Linked with Alterations in Mitochondrial Membrane Potential in Barrett's Esophagus.

• Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments.

• Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer.

• The RESTORE Randomized Controlled Trial: Impact of a Multidisciplinary Rehabilitative Program on Cardiorespiratory Fitness in Esophagogastric cancer Survivorship.

• Unravelling HDL-Looking beyond the Cholesterol Surface to the Quality Within.

• Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review.

• Patient experiences of a physiotherapy-led multidisciplinary rehabilitative intervention after successful treatment for oesophago-gastric cancer.

2017

• Multidisciplinary rehabilitation across the esophageal cancer journey.

• Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.

• Fatty Acids and NLRP3 Inflammasome-Mediated Inflammation in Metabolic Tissues.

• Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.

• The Epidemiology of Esophageal Adenocarcinoma.

• Reduced fitness and physical functioning are long-term sequelae after curative treatment for esophageal cancer: a matched control study.

• HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.

• Effects of a multimodal rehabilitation programme on inflammation and oxidative stress in oesophageal cancer survivors: the ReStOre feasibility study.

2016

• Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.

• High-Density Lipoprotein Proteomic Composition, and not Efflux Capacity, Reflects Differential Modulation of Reverse Cholesterol Transport by Saturated and Monounsaturated Fat Diets.

• Examining the connectivity between different cellular processes in the Barrett tissue microenvironment.

• Role of body composition and metabolic profile in Barrett's oesophagus and progression to cancer.

• Prospective Study of Malabsorption and Malnutrition After Esophageal and Gastric Cancer Surgery.

• Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma.

• Age-specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium.

2015

• Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity.

• The role of energy metabolism in driving disease progression in inflammatory, hypoxic and angiogenic microenvironments.

• Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett's oesophagus.

• The role of inflammation in cancer of the esophagus.

2014

• Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study.

• Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans.

• A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia.

• British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

• The esophagitis to adenocarcinoma sequence; the role of inflammation.

2012

• Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer.

• Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment.

• Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer.

• Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus.

• Visceral obesity, metabolic syndrome, insulin resistance and cancer.

2011

• Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.

• Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

• Increasing incidence of Barrett's oesophagus: a population-based study.

• Definition and classification of cancer cachexia: an international consensus.

2009

• A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.

2008

• Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state.

2007

• Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.

2006

• Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.

• Gastroesophageal reflux disease and physical activity.

• Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity.

AllCaN Oesophageal

If you have any questions for a specific AllCaN Team member,reach out to them here.

AllCaN Team